COPD program marketing: flare and 911 lines, reversal and stem cell claims, oxygen suppliers and referrals

A COPD program speaks to people who get winded on the stairs, who cough every morning, who carry an oxygen tank to the grocery store, and to the family members who worry about the next flare. The program may sit inside a pulmonology practice, a primary care group with a chronic lung clinic, a hospital outpatient department or a rehab center. This guide covers what the federal sources say about COPD, how to write about treatment without promising to reverse lung damage, why stem cell offers for COPD are a problem, where the 911 line belongs, how to point people to quit support, and how to work with home oxygen suppliers without crossing the anti-kickback line.

Seven related topics have their own guides and are not repeated here. Condition pages, breathing quizzes and lung test pages are covered in our guide to pulmonology practice marketing, and Medicare rules for pulmonary rehab in our guide to cardiac and pulmonary rehab marketing. Quit programs are covered in our guide to smoking cessation program marketing, and screening for people who smoked in our guide to lung cancer screening marketing. Cell therapy offers are covered in full in our guide to stem cell clinic advertising, home equipment in our guide to DME supplier marketing, and between-visit programs in our guide to remote patient monitoring marketing.

What NHLBI and MedlinePlus say

The National Heart, Lung, and Blood Institute (NHLBI) leads federal research on COPD, and MedlinePlus from the National Library of Medicine publishes the federal patient pages. The points that shape a COPD program’s marketing:

• The NHLBI What Is COPD? page (last updated November 8, 2024, about two years old) calls COPD a progressive disease whose symptoms worsen over time and can limit routine activities. It says that although there is no cure, treatments and lifestyle changes such as quitting smoking can help people feel better, stay more active and slow the progress of the disease, and that some people may also need oxygen therapy, pulmonary rehabilitation or medicines to treat complications.
• The NHLBI Living With COPD page (last updated October 6, 2024) says COPD has no cure yet, calls a sudden worsening of symptoms a flare-up, and says infections, lung irritants and reflux can raise the risk of one. It tells people to call their provider if symptoms are worsening or they have signs of infection such as a fever, and to seek emergency care for a severe flare-up. It also says heart attacks, strokes and other cardiovascular events are more likely during a flare-up and in the weeks and months after.
• The NHLBI COPD Symptoms page (last updated October 4, 2024) says a person, or family or friends if the person cannot, should call 911 for a hard time catching their breath or talking, lips or fingernails turning blue or gray, not being mentally alert, a very fast heartbeat, or a recommended treatment that is not working.
• The NHLBI COPD Treatment page (last updated October 6, 2024) tells people to discuss a plan with their provider for treating a flare-up, describes pulmonary rehabilitation as a supervised program of exercise training, health education and breathing techniques, and says oxygen therapy is for people whose blood oxygen levels are too low. It says oxygen poses a fire risk, so people should never smoke or use flammable materials when using it.
• The MedlinePlus encyclopedia article Chronic obstructive pulmonary disease (COPD) (review date April 10, 2025) says there is no cure for COPD, that quitting smoking is the best way to slow lung damage, that the disease will get worse more quickly if a person does not stop smoking, and that pulmonary rehabilitation does not cure COPD.
• The MedlinePlus patient instructions Chronic obstructive pulmonary disease, adults, discharge (review date May 4, 2026) tell people to contact their provider if breathing is getting harder, faster than before or shallow, or if it is difficult to speak even a few words without being short of breath. The MedlinePlus COPD page (last updated September 18, 2026) says COPD makes it hard to breathe and gets worse over time.

The NHLBI pages are about two years old, and both NHLBI and MedlinePlus say there is no cure. Before relaying that line, we checked for anything newer. A search of FDA drug label data through openFDA on October 30, 2026 returned labels updated as recently as September 2026 that name COPD in their indications; they are labelled for maintenance treatment or for treating flares, and none we found describes a cure or a reversal of lung damage. The FDA list of Approved Cellular and Gene Therapy Products (content current as of September 17, 2026) names no product for COPD or any other lung disease. The agency wording on cure therefore still stands, and a page can say that treatment options keep developing without naming them. Run the same check at each review.

Two points shape the marketing. First, COPD gets worse over time and the sources describe slowing it, not undoing it, so a page that promises new lungs says more than any source here. Second, NHLBI says to seek emergency care for a severe flare-up, so every page, phone line and message tool has to put the 911 signs ahead of the booking path.

“Reverse your COPD” and other claims that need rewriting

Google’s search suggestions, which we checked on October 30, 2026, offer “copd cure”, “copd curable” and “copd cure news” to a person who starts typing “copd cure”, “can copd be reversed if you quit smoking” and “can copd be reversed with exercise” after “can copd be reversed”, and “copd clinic near me” and “copd doctor near me” for the local searches. A program page can answer those questions honestly: quote NHLBI that there is no cure, say treatment and quitting smoking can help people feel better and slow the disease, and say the plan depends on how severe the COPD is.

Phrases that need rewriting:

• “Reverse your COPD.” NHLBI and MedlinePlus say there is no cure, and MedlinePlus describes slowing lung damage. Remove it, and describe what treatment aims to do in the agency terms.
• “Throw away your oxygen tank.” A result promise, and it may lead a person to stop a prescribed treatment. Remove it.
• “Breathe like you did at 30.” An implied result with no source. Remove it, and describe the program instead.
• “Rehab heals damaged lungs.” MedlinePlus says pulmonary rehabilitation does not cure COPD. Quote NHLBI on what rehab is, and remove the promise.
• “The newest inhaler cuts flare-ups in half.” An outcome number with no source and an implied product. Remove it, and name no product.
• “It’s never too late: quit and your lungs will heal.” MedlinePlus says quitting is the best way to slow lung damage. Quote that line and remove the healing promise.

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices, services or cosmetics. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that an advertiser is responsible for the claims its ads convey, including implied ones. “Get your life back” next to a photo of a hiker is a health benefit claim even without a number.

Emergency signs and 911 on every page and in every tool

A COPD program gets calls and messages from people who are short of breath right now, and a family member typing for them. Put the NHLBI 911 list above the booking button, in plain words: call 911 if you are having a hard time catching your breath or talking, if your lips or fingernails turn blue or gray, if you are not alert, if your heart is beating very fast, or if the treatment your provider recommended is not working. Add a second line for the program’s own number: if your breathing is getting harder or faster than before, or you have signs of infection such as a fever, call [phone]. Ask the clinicians to review both lines and each flare-up plan template before they go live.

The same wording belongs in voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools. A tool should hand any message about trouble breathing to the 911 line and alert staff, and should never offer the next open slot to a person who describes those signs. Our guides to the AI chatbot on a practice website and answering service versus AI receptionist cover how tools hand off these messages, and our guide to transitional care management outreach covers calls after a hospital stay.

Phrases that need rewriting:

• “Short of breath? Book online.” Put the 911 line and the program’s number first, and the booking form after it.
• “Text us your oxygen reading and we’ll tell you what to do.” A text line is not watched in real time. Say who reads messages and when, and give 911 for emergencies.
• “Skip the ER, call us instead.” NHLBI says to seek emergency care for a severe flare-up. Remove it.

Stem cell and “lung regeneration” offers

Search suggestions for “stem cell copd” include clinics abroad and therapy offers, and COPD patients receive these ads. The FDA page Important Patient and Consumer Information About Regenerative Medicine Therapies (content current as of April 8, 2024, older than two years) says regenerative medicine therapies have not been approved for the treatment of any cardiovascular or pulmonary (lung) diseases, such as heart disease, emphysema, or chronic obstructive pulmonary disease (COPD). It says these products require FDA licensure or approval to be marketed, that FDA has received reports of blindness, tumor formation and infections from unapproved products, and that a person charged for these products or offered them outside of a clinical trial is likely being deceived and offered a product illegally. It also says that listing on clinicaltrials.gov or registration with FDA does not mean a product is legally marketed.

Because that page is older than two years, we checked the FDA list of Approved Cellular and Gene Therapy Products (content current as of September 17, 2026) on October 30, 2026. It names no product for COPD, emphysema or any other lung disease. A COPD program should not offer, advertise or refer for cell, fat-derived, cord blood, amniotic or exosome products for COPD outside an FDA-overseen trial. If the program takes part in a trial, recruitment follows our guide to clinical trial recruitment ads, and the ad describes a study, not a treatment.

Phrases that need rewriting:

• “Regenerate lung tissue with your own stem cells.” FDA says these therapies are not approved for COPD. Remove it.
• “Registered with FDA and listed on clinicaltrials.gov.” FDA says neither means a product is legally marketed. Remove it.
• “Ask us about cell therapy options.” Remove it, unless the page describes an FDA-overseen study with its own recruitment rules.

Quit-smoking support without overpromising

The MedlinePlus patient instructions Smoking and COPD (review date October 19, 2025) say quitting smoking is the best thing a person with COPD can do to protect their lungs and keep symptoms from getting worse, that the ways to quit include medicines, nicotine replacement therapy, support groups, counseling and classes, and to ask a health care provider for help. A COPD program page can say the program helps people quit, describe what the help includes, and link to Smokefree.gov, the federal quit site run by the National Cancer Institute, which offers quit plans, a text program and an app.

Keep the tone on the patient’s side: a person with COPD who still smokes has heard the warning before, and a page that blames them will not bring them in. Do not promise that quitting will heal the lungs, name no quit medicine or product, and print no phone number on the page other than the program’s own and 911. Our guide to smoking cessation program marketing covers quit program claims, counseling and coverage in full.

Home oxygen, equipment and supplier relationships

Home oxygen ties a COPD program to equipment suppliers, and that tie needs care. The Medicare.gov page Oxygen equipment and accessories, checked on October 30, 2026, says Part B covers oxygen and oxygen equipment for use at home if the person is eligible, that the doctor or other provider must say the person is not getting enough oxygen, that Medicare will only pay for equipment from suppliers enrolled in Medicare, and that a person with Medicare who uses oxygen rents the equipment from a supplier for 36 months. Quote coverage in those terms, and say the program checks coverage for each patient’s plan rather than saying oxygen “is covered”.

The MedlinePlus patient instructions Oxygen safety (review date January 14, 2026) say no one should smoke in a room where oxygen is used, to put a “NO SMOKING” sign in every room where oxygen is used, and to have working smoke detectors and a fire extinguisher. A patient education page can repeat those steps with the date, and a quit-smoking page should mention them.

For devices the program sells or recommends, such as home breathing trainers or pulse oximeters, describe them in the terms of their FDA status. The FDA page Premarket Notification 510(k) (content current as of August 22, 2024) says FDA’s order finding a device substantially equivalent “clears” it for commercial distribution, and under 21 CFR 807.97, any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding. Our guide to medical device marketing claims covers intended use. Supplements sold as lung cleanses raise the same problem: the FDA Questions and Answers on Dietary Supplements (content current as of August 27, 2026) says FDA does not have the authority to approve dietary supplements before they are marketed. Name no product and make no disease claim; our guide to selling supplements in a medical practice covers the rules.

Under 42 U.S.C. 1320a-7b(b), the federal anti-kickback statute, it is a crime to knowingly and willfully offer, pay, solicit or receive any remuneration to induce or reward referrals of items or services payable by a federal health care program. Rules on referral fees are also set state by state.

For a COPD program, keep these points:

• Do not accept free staff, free respiratory therapists in the clinic, free marketing or event sponsorship from an oxygen or equipment supplier tied to orders, without counsel’s review.
• Give patients a choice of enrolled suppliers, and do not steer orders to one supplier in exchange for anything of value.
• Do not accept payments or marketing help from a drug maker or pharmacy tied to prescriptions; our guide to Open Payments covers reported payments from manufacturers.
• Referral programs with primary care, urgent care, home health and hospital discharge teams follow our guides to patient and physician referrals and home health agency marketing.
• Breathing classes at senior centers follow our guide to patient education seminars, and programs that see Medicaid patients follow our guide to marketing to Medicaid patients.

Free breathing tests, prices and coverage

Free lung function checks at health fairs and pharmacies are a familiar channel for COPD programs. A “free” test follows 16 CFR 251.1, which says a free offer must not be recouped through a raised price or a reduced quantity or quality elsewhere, and the terms of the offer should be stated at the outset. A screening reading is not a diagnosis, and the event page should say a provider diagnoses COPD from symptoms, history and test results. Our guide to health fair screening events covers the event side, and our guides to advertising cash prices and good faith estimates for self-pay patients cover self-pay programs.

Privacy, pixels and ads

A visit to a COPD page, an oxygen question or a rehab request says something about a person’s health, and a form that asks about smoking or oxygen use says more. Keep form answers, bookings and page clicks out of tracking pixels and ad platform tools unless a written agreement covers them; our guide to tracking pixels on practice websites covers the setup. The Google Ads personalized advertising policy lists health among its sensitive interest categories and restricts targeting based on it. Ads can target by place and by search terms, and should not be built from a list of patients with COPD or people who use oxygen.

Under 45 CFR 164.501, a reminder about the practice’s own treatment for an individual, such as a rehab session or a flu shot visit, can fall outside the definition of marketing, while a message that promotes a third party’s product, such as a supplier’s equipment or a drug maker’s program, generally needs a signed authorization under 45 CFR 164.508. Reminder texts name no condition, no result and no product in the message text.

Patient stories

A story from a patient who walks farther after rehab is the strongest pull a COPD program has, and the hardest to use fairly for a disease that gets worse over time. Under 16 CFR 255.2, an ad that shows one person’s result on a key attribute is likely to be read as what others will generally achieve, unless the advertiser has substantiation for that or clearly and conspicuously discloses what people can generally expect. A story should not say the patient stopped oxygen or got their lungs back, and should add a plain line that COPD has no cure and results differ.

Get a signed authorization under 45 CFR 164.508 where the practice is a covered entity, and consent for any photo or video. Name no medicine, device or supplier, say if the patient received anything for taking part, and let them review the final version. Our guides to patient photo consent and testimonials and before and after photos cover the full rules.

Illustration: two COPD program pages

Illustration: a page reads “Reverse your COPD and throw away your oxygen tank. Our lung regeneration program uses your own stem cells, registered with FDA. Short of breath? Skip the ER and book online. Free oxygen equipment from our partner supplier.” It promises a reversal the agencies say is not possible, offers a cell product FDA says is not approved for COPD, misreads FDA registration, sends an emergency to a booking form, and ties equipment to one supplier.

Illustration: a second page for the same practice reads “Call 911 if you are having a hard time catching your breath or talking, if your lips or fingernails turn blue or gray, or if the treatment your provider recommended is not working. If your breathing is getting harder or faster than before, or you have a fever, call [phone]. At [Practice name], [Clinician name, license] leads our COPD program. There is no cure for COPD, but treatment, rehab and quitting smoking can help you feel better, stay active and slow the disease. We help you make a plan for flare-ups, and if you need home oxygen, you choose the supplier. Call [phone] during [days and hours].” It puts the emergency line first, quotes what the sources say, and promises nothing it cannot show.

Checklist before a COPD campaign goes live

• NHLBI and MedlinePlus pages named and dated, with pages about two years old or older marked and checked against newer FDA label data and the FDA cell and gene therapy list at each review.
• The NHLBI 911 signs above any booking button, plus the program’s number for worsening breathing or fever, in voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools.
• No cure, reversal, “new lungs” or “off oxygen” claims; slowing the disease and feeling better described in the agency terms.
• No stem cell, exosome or other regenerative offers for COPD outside an FDA-overseen trial; no “registered with FDA” wording as a selling point.
• Quit support described plainly, linked to Smokefree.gov, with no healing promise, no product names and no phone numbers other than the program’s and 911.
• Oxygen coverage quoted from Medicare.gov and checked per patient; patients choose among enrolled suppliers; oxygen fire safety steps included.
• Devices described as FDA cleared only where true and only for the cleared use; no supplement or lung cleanse claims.
• No free staff, sponsorship or marketing help from suppliers, pharmacies or drug makers tied to orders or prescriptions without counsel’s review.
• Free breathing tests follow 16 CFR 251.1 and say a provider diagnoses COPD; prices and refund terms stated.
• Form answers and bookings stay out of pixels and ad audiences; targeting by place and search terms only.
• Stories have signed authorizations, make no results claim, and say COPD has no cure and results differ.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses, including pulmonology, primary care and rehab practices that run COPD programs. For a COPD program, that means a site that quotes NHLBI and MedlinePlus as written and dated, puts the 911 signs and the program’s number above the booking button, answers “can COPD be reversed” searches without a promise, and keeps stem cell offers and supplier ties off the page, plus referral and appointment request pages that keep answers off the web and away from tracking tools. Our front desk tools hand breathing complaints to the 911 line and the on-call number, and do not triage symptoms. We do not decide who needs treatment; your clinicians do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• NHLBI: What Is COPD? (last updated November 8, 2024)
• NHLBI: COPD Symptoms (last updated October 4, 2024)
• NHLBI: COPD Treatment (last updated October 6, 2024)
• NHLBI: Living With COPD (last updated October 6, 2024)
• MedlinePlus: COPD (last updated September 18, 2026)
• MedlinePlus encyclopedia: Chronic obstructive pulmonary disease (COPD) (review date April 10, 2025)
• MedlinePlus: Chronic obstructive pulmonary disease, adults, discharge (review date May 4, 2026)
• MedlinePlus: Smoking and COPD (review date October 19, 2025)
• MedlinePlus: Oxygen safety (review date January 14, 2026)
• openFDA: Drug labeling API (searched October 30, 2026)
• FDA: Important Patient and Consumer Information About Regenerative Medicine Therapies (content current as of April 8, 2024)
• FDA: Approved Cellular and Gene Therapy Products (content current as of September 17, 2026)
• Smokefree.gov, National Cancer Institute (checked October 30, 2026)
• Medicare.gov: Oxygen equipment and accessories (checked October 30, 2026)
• FDA: Premarket Notification 510(k) (content current as of August 22, 2024)
• 21 CFR 807.97: Misbranding by reference to premarket notification
• FDA: Questions and Answers on Dietary Supplements (content current as of August 27, 2026)
• 15 U.S.C. 45: Unfair methods of competition unlawful
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 251.1: Guide concerning use of the word free and similar representations
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs
• 45 CFR 164.501: Definitions
• 45 CFR 164.508: Uses and disclosures for which an authorization is required
• 16 CFR 255.2: Consumer endorsements
• Google Ads: Personalized advertising policy

More in Physician specialty marketing